Immuno-Biological Laboratories Co., Ltd (IBL)

Immuno-Biological Laboratories Co., Ltd (IBL) is a Japanese company known for its antibody and ELISA manufacturing for global use. Since its founding in 1982, the company has been dedicated to the vision of "Supplying valuable antibodies to save people fighting against diseases all over the world," reflecting the spirit and passion of its founder and President, Mr. Tsutomu Seito, a pioneer of Monoclonal antibody. IBL has a rich history in antibody development, having utilized over 5,000 antigens and provided more than 10,000 contract services since its establishment. Offering around 500 products, including over 120 ELISA products and more than 350 antibodies, the company has established a strong global supply network through valued international distributors in over 80 countries. Maintaining ISO13485 certification since 2009, IBL ensures high-quality products manufactured and controlled in-house at its head office and main laboratory in Japan. The company's focus areas include inflammatory diseases, kidney diseases, aging, neurodegenerative disorders, and glucose/lipid metabolism. With its latest investment of ¥1.39BPost-IPO Debt by Whiz Partners in December 2016, IBL has demonstrated its potential for growth and innovation in the biotechnology, healthcare, and pharmaceutical industries.